Placental Origins of Preeclampsia: Potential Therapeutic Targets

Abstract

Preeclampsia (PE) remains a leading cause of maternal and perinatal morbidity and mortality in obstetrics worldwide. No effective treatments to reduce its incidence and severity in clinical practice are currently available. A variety of hypotheses have been generated aiming to explain the origins of PE, notably being the genetic predispositions and placental dysfunction. As regard to placental dysfunction, much progress has been made in basic research and several potential therapeutic targets have been identified. This review will discuss in detail the potential therapeutic targets in PE models including uteroplacental blood flow, oxidative stress, vasoactive factors and inflammation/immune response, and introduce the evolving technologies for placental research nowadays.

Keywords

preeclampsia / placental dysfunction / therapeutic targets

References

[1] MolBWJ, RobertsCT, ThangaratinamS, et al.. Preeclampsia. Lancet, 2016, 387(10022): 999-1011

[2] SouzaJ, GülmezogluA, VogelJ, et al.. Moving beyond essential interventions for reduction of maternal mortality (the WHO Multicountry Survey on Maternal and Newborn Health): a cross-sectional study. Lancet, 2013, 381(9879): 1747-1755

[3] McDonaldS, MalinowskiA, ZhouQ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J, 2008, 156(5): 918-930

[4] ChappellLC, DuckworthS, SeedPT, et al.. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation, 2013, 128(19): 2121-2131

[5] PoonL, KametasN, MaizN, et al.. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension, 2009, 53(5): 812-818

[6] AskieL, DuleyL, Henderson-SmartD, et al.. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet, 2007, 369(9575): 1791-1798

[7] KublickieneK, NisellH, PostonL, et al.. Modulation of vascular tone by nitric oxide and endothelin 1 in myometrial resistance arteries from pregnant women at term. Am J Obstet Gynecol, 2000, 182(1): 87-93 Pt 1

[8] KulandaveluS, WhiteleyK, QuD, et al.. Endothelial nitric oxide synthase deficiency reduces uterine blood flow, spiral artery elongation, and placental oxygenation in pregnant mice. Hypertension, 2012, 60(1): 231-238

[9] Vadillo-OrtegaF, Perichart-PereraO, EspinoS, et al.. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ, 2011, 342: d2901

[10] CuretonN, KorotkovaI, BakerB, et al.. Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy. Theranostics, 2017, 7(15): 3715-3731

[11] WareingM, MyersJ, O’HaraM, et al.. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab, 2005, 90(5): 2550-2555

[12] PaauwN, TerstappenF, GanzevoortW, et al.. Sildenafil During Pregnancy: A Preclinical Meta-Analysis on Fetal Growth and Maternal Blood Pressure. Hypertension, 2017, 70(5): 998-1006

[13] DavidA, TorondelB, ZacharyI, et al.. Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep. Gene Ther, 2008, 15(19): 1344-1350

[14] MehtaV, Abi-NaderK, PeeblesD, et al.. Long-term increase in uterine blood flow is achieved by local overexpression of VEGF-A(165) in the uterine arteries of pregnant sheep. Gene Ther, 2012, 19(9): 925-935

[15] DesforgesM, RogueA, PearsonN, et al.. In Vitro Human Placental Studies to Support Adenovirus-Mediated VEGF-DANAC Maternal Gene Therapy for the Treatment of Severe Early-Onset Fetal Growth Restriction. Hum Gene Ther Clin Dev, 2018, 29(1): 10-23

[16] BenoitC, ZaveczJ, WangY. Vasoreactivity of chorionic plate arteries in response to vasoconstrictors produced by preeclamptic placentas. Placenta, 2007, 28(5–6): 498-504

[17] HeM, LiF, YangM, et al.. Impairment of BKca channels in human placental chorionic plate arteries is potentially relevant to the development of preeclampsia. Hypertens Res, 2018, 41(2): 126-134

[18] LiF, HeM, XieY, et al.. Involvement of dysregulated IKCa and SKCa channels in preeclampsia. Placenta, 2017, 58: 9-16

[19] LiF, HeM, YangM, et al.. Alteration of heat shock protein 20 expression in preeclamptic patients and its effect in vascular and coagulation function. Front Med, 2018, 12(5): 542-549

[20] BurtonG, JauniauxE. Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig, 2004, 11(6): 342-352

[21] PatilS, KodliwadmathM, KodliwadmathM. Lipid peroxidation and antioxidant activity in complicated pregnancies. Clin Exp Obstet Gynecol, 2009, 36(2): 110-112

[22] VakaV, McMasterK, CunninghamMJ, et al.. Role of Mitochondrial Dysfunction and Reactive Oxygen Species in Mediating Hypertension in the Reduced Uterine Perfusion Pressure Rat Model of Preeclampsia. Hypertension, 2018, 72(3): 703-711

[23] AljunaidyM, MortonJ, KirschenmanR, et al.. Maternal treatment with a placental-targeted antioxidant (MitoQ) impacts offspring cardiovascular function in a rat model of prenatal hypoxia. Pharmacol Res, 2018, 134: 332-342

[24] LanoixD, GuérinP, VaillancourtC. Placental melatonin production and melatonin receptor expression are altered in preeclampsia: new insights into the role of this hormone in pregnancy. J Pineal Res, 2012, 53(4): 417-425

[25] ChenY, XuD, WangJ, et al.. Melatonin protects against lipopolysaccharide-induced intrauterine fetal death and growth retardation in mice. J Pineal Res, 2006, 40(1): 40-47

[26] BrownfootF, TongS, HannanN, et al.. Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia. Hypertension, 2015, 66(3): 687-697

[27] PoudelR, StanleyJ, Rueda-ClausenC, et al.. Effects of Resveratrol in Pregnancy Using Murine Models with Reduced Blood Supply to the Uterus. PLoS One, 2013, 8(5): e64401

[28] NezuM, SoumaT, YuL, et al.. Nrf2 inactivation enhances placental angiogenesis in a preeclampsia mouse model and improves maternal and fetal outcomes. Sci Signal, 2017, 10(479): eaa-5711 pii

[29] MaynardS, MinJ, MerchanJ, et al.. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Investig, 2003, 111(5): 649-658

[30] ZhouQ, QiaoF, ZhaoC, et al.. Hypoxic trophoblast-derived sFlt-1 may contribute to endothelial dysfunction: implication for the mechanism of trophoblast-endothelial dysfunction in preeclampsia. Cell Biol Int, 2011, 35(1): 61-66

[31] YuJ, JiaJ, GuoX, et al.. Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery. Placenta, 2017, 58: 1-8

[32] SpradleyF, TanA, JooW, et al.. Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension. Hypertension, 2016, 67(4): 740-747

[33] BalanA, Szaingurten-SolodkinI, SwissaS, et al.. The effects of pravastatin on the normal human placenta: Lessons from ex-vivo models. PLoS One, 2017, 12(2): e0172174

[34] RammaW, AhmedA. Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol, 2014, 101(100): 153-160

[35] GeorgeE, GrangerJ. Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1. Hypertension, 2012, 60(2): 507-511

[36] GeorgeE, PaleiA, GrangerJ. Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications. Curr Opin Nephrol Hypertens, 2012, 21(2): 157-162

[37] AlexanderB, RinewaltA, CockrellK, et al.. Endothelin Type A Receptor Blockade Attenuates the Hypertension in Response to Chronic Reductions in Uterine Perfusion Pressure. Hypertension, 2001, 37(2): 485-489

[38] ThaeteL, KhanS, SynowiecS, et al.. Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy. Life Sci, 2012, 91(13–14): 583-586

[39] MazzucaM, LiW, ReslanO, et al.. Downregulation of microvascular endothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy. Hypertension, 2014, 64(3): 632-643

[40] SiddiquiA, IraniR, BlackwellS, et al.. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension, 2010, 55(2): 386-393

[41] XiaY, RaminS, KellemsR. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension, 2007, 50(2): 269-275

[42] ZhouC, AhmadS, MiT, et al.. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension, 2008, 51(4): 1010-1019

[43] LaMarcaB, WallaceK, HerseF, et al.. Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes. Hypertension, 2011, 57(4): 865-871

[44] CunninghamMJ, CastilloJ, IbrahimT, et al.. AT1–AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats. Hypertension, 2018, 71(5): 886-893

[45] Laresgoiti-ServitjeE. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol, 2013, 94(2): 247-257

[46] FaasM, De VosP. Innate immune cells in the placental bed in healthy pregnancy and preeclampsia. Placenta, 2018, 69: 125-133

[47] RobsonA, HarrisL, InnesB, et al.. Uterine natural killer cells initiate spiral artery remodeling in human pregnancy. FASEB J, 2012, 26(12): 4876-4885

[48] LaMarcaB, BennettW, AlexanderB, et al.. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. Hypertension, 2005, 46(4): 1022-1025

[49] LaMarcaB, SpeedJ, FournierL, et al.. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade. Hypertension, 2008, 52(6): 1161-1167

[50] Santner-NananB, PeekM, KhanamR, et al.. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol, 2009, 183(11): 7023-7030

[51] ToldiG, RigoJJ, StenczerB, et al.. Increased prevalence of IL-17-producing peripheral blood lymphocytes in pre-eclampsia. Am J Reprod Immunol, 2011, 66(3): 223-229

[52] CareA, BourqueS, MortonJ, et al.. Reduction in Regulatory T Cells in Early Pregnancy Causes Uterine Artery Dysfunction in Mice. Hypertension, 2018, 72(1): 177-187

[53] CorneliusDC, AmaralLM, HarmonA, et al.. An increased population of regulatory T cells improves the pathophysiology of placental ischemia in a rat model of preeclampsia. Am J Physiol Regul Integr Comp Physi, 2015, 309(8): R884-891

[54] HarmonA, CorneliusD, AmaralL, et al.. IL-10 supplementation increases Tregs and decreases hypertension in the RUPP rat model of preeclampsia. Hypertens Pregnancy, 2015, 34(3): 291-306

[55] OuyangY, MouilletJ, CoyneC, et al.. Review: placenta-specific microRNAs in exosomes — good things come in nano-packages. Placenta, 2014, 35: S69-73 Suppl)

[56] Motta-MejiaC, KandzijaN, ZhangW, et al.. Placental vesicles carry active endothelial nitric oxide synthase and their activity is reduced in preeclampsia. Hypertension, 2017, 70(2): 372-381

[57] TruongG, GuanzonD, KinhalV, et al.. Oxygen tension regulates the miRNA profile and bioactivity of exosomes released from extravillous trophoblast cells — Liquid biopsies for monitoring complications of pregnancy. PLoS One, 2017, 12(3): e0174514

[58] TobitaT, KiyozumiD, IkawaM. Placenta-specific gene manipulation using lentiviral vector and its application. Placenta, 2017, 59(1): S37-S43

[59] ZhangB, TanL, YuY, et al.. Placenta-specific drug delivery by trophoblast-targeted nanoparticles in mice. Theranostics, 2018, 8(10): 2765-2781

[60] YuQ, QiuY, WangX, et al.. Efficient siRNA transfer to knock down a placenta specific lncRNA using RGD-modified nano-liposome: A new preeclampsia-like mouse model. Int J Pharmac, 2018, 546(1–2): 115-124